E2F-1 as an anticancer drug target

  • Joseph R. Bertino | bertinoj@umdnj.edu Departments of Medicine and Pharmacology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry, New Brunswick, United States.
  • Debabrata Banerjee Departments of Medicine and Pharmacology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry, New Brunswick, United States.

Abstract

Mounting evidence indicates that the E2F transcription factors play an essential role in all aspects of cellular functions. Many human malignancies have been shown to overexpress one or more of the ‘‘activating’’ E2Fs. In some circumstances, down regulation as well as overexpression of E2F-1, leads to inhibition of cell growth. The emphasis in this review is placed on new data implicating microRNAs in the regulation of E2F activity and the efforts thus far to target this activity in order to cause tumor regression.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-12-14
Info
Issue
Section
Reviews
Keywords:
E2F-1 - Retinoblastoma protein - Cancer - MicroRNAs
Statistics
  • Abstract views: 1089

  • FULL TEXT: 170
How to Cite
Bertino, J. R., & Banerjee, D. (2011). E2F-1 as an anticancer drug target. Oncology Reviews, 3(4), 207-214. https://doi.org/10.4081/oncol.2009.96